阿司匹林预防子痫前期
子痫前期是孕20周后出现高血压伴蛋白尿或终末器官损害,是母胎病残和死亡的重要原因。阿司匹林低于300 mg可不可逆抑制环氧化酶-1,抑制前列腺素和血栓素生成及血小板聚集。个体患者数据Meta分析显示子痫前期率适度降低10%,后续汇总数据Meta分析显示剂量-反应效应,孕16周前起始给药时最大化;阿司匹林循证预防子痫前期试验显示,孕16周前起始每日150 mg夜间给药,在高危人群(早孕期联合筛查识别)中使早产子痫前期发生率降低62%。
要点
- 阿司匹林低于300 mg不可逆抑制环氧化酶-1,抑制前列腺素和血栓素生成,抑制炎症和血小板聚集。
- 个体患者数据Meta分析显示阿司匹林使子痫前期率适度降低10%。
- 阿司匹林循证预防子痫前期试验显示孕16周前起始每日150 mg夜间给药使早产子痫前期发生率降低62%。
核心结论
- 阿司匹林可预防子痫前期,效应受剂量、起始孕周和依从性影响,孕16周前起始给药效果更明显。
- 阿司匹林循证预防子痫前期试验显示孕16周前起始每日150 mg夜间给药使早产子痫前期发生率降低62%。
研究设计与样本
- 本文为综述,总结阿司匹林预防子痫前期及其并发症的证据。
主要发现
- 个体患者数据Meta分析显示阿司匹林使子痫前期率适度降低10%。
- 后续汇总数据Meta分析显示阿司匹林对子痫前期率有剂量-反应效应,孕16周前起始给药时最大化。
- 阿司匹林循证预防子痫前期试验显示孕16周前起始每日150 mg夜间给药使早产子痫前期发生率降低62%。
- 阿司匹林循证预防子痫前期试验数据二次分析显示新生儿重症监护病房住院时间较安慰剂缩短68%,主要因孕32周前子痫前期分娩减少。
- 阿司匹林获益在不同母体特征亚组中相似,但慢性高血压者未见明显获益;依从性好的女性效应量更明显。
关键数值与推荐
- 阿司匹林低于300 mg选择性不可逆抑制环氧化酶-1。
- 阿司匹林循证预防子痫前期试验中阿司匹林每日150 mg,孕16周前起始,夜间给药,用于早孕期联合筛查识别的高危人群。
- 随机试验通常把握度不足,无法研究阿司匹林对胎儿生长受限和死产等其他胎盘相关不良结局发生率的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 随机试验通常把握度不足,无法研究阿司匹林对胎儿生长受限和死产等其他胎盘相关不良结局发生率的影响。
- 既往随机试验结果不一致,很大程度上可由试验对象选择、纳入女性基线风险、阿司匹林剂量、预防起始孕周和子痫前期定义的高度异质性解释。
- 慢性高血压者未见明显获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preeclampsia is defined as hypertension arising after 20 weeks of gestational age with proteinuria or other signs of end-organ damage and is an important cause of maternal and perinatal morbidity and mortality, particularly when of early onset. Although a significant amount of research has been dedicated in identifying preventive measures for preeclampsia, the incidence of the condition has been relatively unchanged in the last decades. This could be attributed to the fact that the underlying pathophysiology of preeclampsia is not entirely understood. There is increasing evidence suggesting that suboptimal trophoblastic invasion leads to an imbalance of angiogenic and antiangiogenic proteins, ultimately causing widespread inflammation and endothelial damage, increased platelet aggregation, and thrombotic events with placental infarcts. Aspirin at doses below 300 mg selectively and irreversibly inactivates the cyclooxygenase-1 enzyme, suppressing the production of prostaglandins and thromboxane and inhibiting inflammation and platelet aggregation. Such an effect has led to the hypothesis that aspirin could be useful for preventing preeclampsia. The first possible link between the use of aspirin and the prevention of preeclampsia was suggested by a case report published in 1978, followed by the first randomized controlled trial published in 1985. Since then, numerous randomized trials have been published, reporting the safety of the use of aspirin in pregnancy and the inconsistent effects of aspirin on the rates of preeclampsia. These inconsistencies, however, can be largely explained by a high degree of heterogeneity regarding the selection of trial participants, baseline risk of the included women, dosage of aspirin, gestational age of prophylaxis initiation, and preeclampsia definition. An individual patient data meta-analysis has indicated a modest 10% reduction in preeclampsia rates with the use of aspirin, but later meta-analyses of aggregate data have revealed a dose-response effect of aspirin on preeclampsia rates, which is maximized when the medication is initiated before 16 weeks of gestational age. Recently, the Aspirin for Evidence-Based Preeclampsia Prevention trial has revealed that aspirin at a daily dosage of 150 mg, initiated before 16 weeks of gestational age, and given at night to a high-risk population, identified by a combined first trimester screening test, reduces the incidence of preterm preeclampsia by 62%. A secondary analysis of the Aspirin for Evidence-Based Preeclampsia Prevention trial data also indicated a reduction in the length of stay in the neonatal intensive care unit by 68% compared with placebo, mainly because of a reduction in births before 32 weeks of gestational age with preeclampsia. The beneficial effect of aspirin has been found to be similar in subgroups according to different maternal characteristics, except for the presence of chronic hypertension, where no beneficial effect is evident. In addition, the effect size of aspirin has been found to be more pronounced in women with good compliance to treatment. In general, randomized trials are underpowered to investigate the treatment effect of aspirin on the rates of other placental-associated adverse outcomes such as fetal growth restriction and stillbirth. This article summarizes the evidence around aspirin for the prevention of preeclampsia and its complications.
引用
- Rolnik DL, Nicolaides KH, Poon LC, et al. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2020. PMID: 32835720. doi:10.1016/j.ajog.2020.08.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。